Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Florkowski, C. M.
Right arrow Articles by Barnett, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Florkowski, C. M.
Right arrow Articles by Barnett, A. H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 40, Issue 1 129-133, Copyright © 1991 by American Diabetes Association

ARTICLES

Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy

CM Florkowski, BR Rowe, S Nightingale, TC Harvey and AH Barnett
Department of Medicine, East Brimingham Hospital, Bordesley Green East, UK.

Increased flux through the polyol pathway mediated by the enzyme aldose reductase may be associated with the development of diabetic neuropathy. Fifty-four diabetic patients (median age 56 yr, range 25-65 yr) with chronic neuropathic symptoms were randomly allocated to placebo or aldose reductase inhibition (300 or 600 mg ponalrestat ICI 128436) groups for 24 wk. Patients with vibration perception thresholds (VPTs) greater than 35 V at the great toe or thermal difference thresholds (TTs) greater than 10 degrees C on the dorsum of the foot were excluded from the trial. No significant changes were observed in symptoms of pain, numbness, or paresthesia between ponalrestat and placebo groups, and there were no improvements in VPT or TT at several sites. Posterior tibial nerve conduction velocity changed from 35.3 +/- 4.9 m/s at baseline to 33.4 +/- 4.0 m/s at 24 wk (NS) with placebo compared with 37.6 +/- 5.6 vs. 37.2 +/- 8.7 m/s (NS) with 300 mg ponalrestat and 34.5 +/- 6.1 vs. 36.2 +/- 6.8 m/s (NS) with 600 mg ponalrestat. Further studies are indicated with intervention at an earlier stage in the evolution of neuropathy and for longer periods.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
S. Misawa, S. Kuwabara, K. Kanai, N. Tamura, M. Nakata, S. Sawai, K. Yagui, and T. Hattori
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics
Neurology, May 23, 2006; 66(10): 1545 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. H. Akamine, T. C. Hohman, D. Nigro, M. H. C. Carvalho, R. d. C. Tostes, and Z. B. Fortes
Minalrestat, an Aldose Reductase Inhibitor, Corrects the Impaired Microvascular Reactivity in Diabetes
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1236 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. A. Greene, J. C. Arezzo, and M. B. Brown
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
Neurology, August 1, 1999; 53(3): 580 - 580.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1991 by the American Diabetes Association.